Imagine if you could trick a cancer cell into becoming a teacher for the immune system. Instead of using risky viruses to rewrite a cell's DNA, this method uses a cocktail of chemical pills to flip a switch in the tumor. This turns the cancer cell into a specialized scout that shows the rest of the body exactly how to find and destroy the remaining tumor.
Most cancer patients do not respond to immunotherapy due to immune evasion and a lack of tumor antigen presentation. Current gene therapies are expensive, risky, and difficult to manufacture using viral vectors.
A high-content screening process that identified 94 small molecules capable of reprogramming cancer cells into dendritic cells.
If you are a drug developer dealing with low patient response rates in solid tumors — this project developed a small-molecule reprogramming platform that converts cancer cells into antigen-presenting cells to trigger personalized immunity.
If you are a biotech firm dealing with the high cost and safety risks of viral vectors — this project developed nanoparticle formulations for the systemic delivery of chemical cocktails to target tumors safely.
If you are a clinic dealing with the complexity of ex vivo cell therapies — this project developed an in vivo reprogramming method that could lead to off-the-shelf, personalized cancer immunotherapies.
Based on available project data, the use of small molecules and nanoparticles aims to create a low-cost and cost-efficient platform compared to complex and costly viral vector manufacturing.
Based on available project data, the project seeks to avoid the manufacturing limitations of viral vectors, though industrial scale-up details are not yet provided.
Based on available project data, the consortium has identified 94 active small molecules, but specific patent or licensing terms are not mentioned.
The project aims to achieve proof-of-concept for chemical reprogramming by the end of 2026.
The platform is designed to work as a standalone treatment or to synergize with existing immunotherapies, such as immune checkpoint blockade, to increase effectiveness.
The consortium is research-heavy, consisting of 4 universities and 1 research institute, with only 1 SME (17% industry ratio). This indicates the project is currently in a high-risk, high-reward discovery phase, leveraging academic expertise in cellular reprogramming and nanoparticles to build a foundation for future commercialization.
Lunds Universitet
Contact us to explore licensing opportunities for the 94 identified small molecules.
